Helen Toma
YOU?
Author Swipe
View article: Immune phenotype in high- versus low-NRF2 high grade serous ovarian cancer and the impact on prognosis
Immune phenotype in high- versus low-NRF2 high grade serous ovarian cancer and the impact on prognosis Open
NRF2 modulates tumor immune microenvironment (IMM) in several cancers. NRF2 is activated in about 50% of high grade serous ovarian cancer (HGSOC), the most aggressive type of ovarian cancer. This study aimed to stratify HGSOC patients’ sam…
View article: Pembrolizumab and lenvatinib in the treatment of recurrent ovarian carcinoma: A single institution experience
Pembrolizumab and lenvatinib in the treatment of recurrent ovarian carcinoma: A single institution experience Open
View article: Alternative treponemal serology assays for diagnosis and confirmation of syphilis in a diagnostic laboratory: a retrospective evaluation of four agglutination assays and one ELISA
Alternative treponemal serology assays for diagnosis and confirmation of syphilis in a diagnostic laboratory: a retrospective evaluation of four agglutination assays and one ELISA Open
The Treponema pallidum particle agglutination (TPPA) assay is no longer available in some settings. Here, we report the results of a clinical laboratory evaluation of alternative treponemal assays, including three T. pallidum hemagglutinat…
View article: 173P NRF2 levels in high grade serous ovarian cancer: Characterization and treatment
173P NRF2 levels in high grade serous ovarian cancer: Characterization and treatment Open
View article: The contribution of household income to rectal cancer patient characteristics, treatment, and outcomes from 2010 to 2020
The contribution of household income to rectal cancer patient characteristics, treatment, and outcomes from 2010 to 2020 Open
View article: <i>CDKN2C</i> -Null Leiomyosarcoma: A Novel, Genomically Distinct Class of <i>TP53</i> / <i>RB1</i> –Wild-Type Tumor With Frequent <i>CIC</i> Genomic Alterations and 1p/19q-Codeletion
<i>CDKN2C</i> -Null Leiomyosarcoma: A Novel, Genomically Distinct Class of <i>TP53</i> / <i>RB1</i> –Wild-Type Tumor With Frequent <i>CIC</i> Genomic Alterations and 1p/19q-Codeletion Open
PURPOSE Leiomyosarcoma (LMS) harbors frequent mutations in TP53 and RB1 but few actionable genomic alterations. Here, we searched for recurrent actionable genomic alterations in LMS that occur in the absence of common untreatable oncogenic…
View article: Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV– Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets
Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV– Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets Open
PURPOSE Vulvar squamous cell carcinoma (vSCC) encompasses two predominant variants: one associated with detectable high-risk strains of human papillomavirus (hrHPV) and a second form often occurring in the context of chronic dermatitis in …
View article: <i>CDKN2C</i>homozygous loss identifies a distinct subtype of<i>TP53/RB1</i>-wildtype leiomyosarcoma with frequent<i>CIC</i>genomic alterations and 1p/19q-codeletion
<i>CDKN2C</i>homozygous loss identifies a distinct subtype of<i>TP53/RB1</i>-wildtype leiomyosarcoma with frequent<i>CIC</i>genomic alterations and 1p/19q-codeletion Open
Purpose Leiomyosarcomas (LMS) harbor frequent inactivation of TP53 and RB1 , and extensive DNA copy number alterations. Here, we describe a distinct recurrent genomic signature in TP53 / RB1 -wildtype uterine LMS. Methods Tissues from 276,…